Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PvRII/Matrix-M Malaria Vaccine in Healthy Thai Adults (MIST3)
NCT05380388Phase 2Not yet recruiting
- Sponsor
- University of Oxford
- Start
- Jan 2027
- Primary completion
- Dec 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PvRII + Matrix-M in malaria (2 arms), sponsored by University of Oxford. Primary endpoints: Solicited local adverse events, Solicited systemic adverse events and 4 more. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
PvRII + Matrix-M
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05380388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05380388.